10 results
The primary objective is to assess diagnostic accuracy of MRDTI/BTI for first and recurrent CVT in patients referred for MRI/MRV in the setting of routine clinical setting. The secondary objectives are to optimize MRDTI/BTI sequences for imaging…
To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with `standard' management by CTPA alone in a…
To compare postamputation pain (phantom limb pain and residual limb pain) one year postoperatively in patients receiving a lower extremity amputation with standard neurectomy versus those who received targeted muscle reinnervation.
The main objective of this trial is to determine whether reusable catheters are not less efficient as single use catheters, measured by symptomatic UTIs. Secondary objectives are adverse events like hospital admissions due to UTIs, urethral damage/…
Our objective is to compare the efficacy of early chest tube removal combined with single-shot PVB versus standard treatment (chest tube for at least 3 days and thoracic epidural analgesia (TEA)) after surgery for PSP. Efficacy is defined as…
The goal of this study is to investigate which treatment(-s) lead to the best outcome by using existing variation of practice.
The primary objective of this study is to measure the number of antigen specific T-cells in the plaque and in blood, and investigate whether these parameters correlate with the phenotype of the atherosclerotic plaque. Secondary objectives are: 1)…
This strategy will result in a reduction reduce the incidence of major adverse cardiovascular events (MACE) defined as death or non-fatal myocardial infarction and appear more efficient than care as usual.
To determine whether CDT in high-risk PE relative to systemic thrombolysis is:- more effective and safer in terms of a reduction of the composite endpoint on all-cause mortality and adverse events defined as treatment failure, major&…
Determine the safety (oncological outcome and toxicity) of an comprehensive treatment combining recent advances in the treatment of high risk prostate cancer